par Desmedt, Christine ;Di Leo, Angelo ;de Azambuja, Evandro ;Larsimont, Denis ;Haibe-Kains, Benjamin ;Selleslags, Jean;Delaloge, Suzette;Duhem, Caroline;Kains, Jean-Pierre;Carly, Birgit;Maerevoet, Marie ;Vindevoghel, Anita;Rouas, Ghizlane;Lallemand, Françoise;Durbecq, Virginie ;Cardoso, Fatima ;Salgado, Roberto;Kraft Rovere, Rodrigo ;Bontempi, Gianluca ;Michiels, Stefan ;Buyse, Marc;Nogaret, Jean-Marie ;Qi, Yuan;Symmans, Fraser;Pusztai, Lajos;D'Hondt, Veronique ;Piccart-Gebhart, Martine ;Sotiriou, Christos
Référence Journal of clinical oncology, 29, 12, page (1578-1586)
Publication Publié, 2011-04
Référence Journal of clinical oncology, 29, 12, page (1578-1586)
Publication Publié, 2011-04
Article révisé par les pairs
Titre: |
|
Auteur: | Desmedt, Christine; Di Leo, Angelo; de Azambuja, Evandro; Larsimont, Denis; Haibe-Kains, Benjamin; Selleslags, Jean; Delaloge, Suzette; Duhem, Caroline; Kains, Jean-Pierre; Carly, Birgit; Maerevoet, Marie; Vindevoghel, Anita; Rouas, Ghizlane; Lallemand, Françoise; Durbecq, Virginie; Cardoso, Fatima; Salgado, Roberto; Kraft Rovere, Rodrigo; Bontempi, Gianluca; Michiels, Stefan; Buyse, Marc; Nogaret, Jean-Marie; Qi, Yuan; Symmans, Fraser; Pusztai, Lajos; D'Hondt, Veronique; Piccart-Gebhart, Martine; Sotiriou, Christos |
Informations sur la publication: | Journal of clinical oncology, 29, 12, page (1578-1586) |
Statut de publication: | Publié, 2011-04 |
Sujet CREF: | Cancérologie |
Sciences biomédicales | |
MeSH keywords: | Antibiotics, Antineoplastic -- adverse effects -- therapeutic use |
Antigens, Neoplasm -- analysis -- genetics | |
Biopsy | |
Breast Neoplasms -- drug therapy -- enzymology -- genetics -- pathology | |
Chemotherapy, Adjuvant | |
DNA Topoisomerases, Type II -- analysis -- genetics | |
DNA-Binding Proteins -- analysis -- antagonists & inhibitors -- genetics | |
Drug Resistance, Neoplasm -- genetics | |
Epirubicin -- adverse effects -- therapeutic use | |
Europe | |
Female | |
Gene Expression Profiling | |
Gene Expression Regulation, Neoplastic | |
Humans | |
Middle Aged | |
Neoadjuvant Therapy | |
Odds Ratio | |
Patient Selection | |
Predictive Value of Tests | |
Prospective Studies | |
Receptor, erbB-2 -- analysis | |
Receptors, Estrogen -- analysis | |
Reproducibility of Results | |
Risk Assessment | |
Risk Factors | |
Texas | |
Treatment Failure | |
Tumor Markers, Biological -- analysis | |
Note générale: | Journal Article |
Multicenter Study | |
Randomized Controlled Trial | |
SCOPUS: ar.j | |
Langue: | Anglais |
Identificateurs: | urn:issn:0732-183X |
info:doi/10.1200/JCO.2010.31.2231 | |
info:pii/JCO.2010.31.2231 | |
info:scp/79955008762 | |
info:pmid/21422418 |